查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1985735

心肺体外迴圈装置市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Cardiopulmonary Bypass Equipment Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心肺体外迴圈设备市场价值将达到 3.2974 亿美元，到 2026 年将成长至 3.4263 亿美元，到 2032 年将达到 4.561 亿美元，复合年增长率为 4.74%。

主要市场统计数据
基准年 2025 3.2974亿美元
预计年份：2026年 3.4263亿美元
预测年份 2032 4.561亿美元
复合年增长率 (%) 4.74%

对心肺体外迴圈设备在临床实践中的定位、采购重点、技术进步和医疗保健决策框架进行策略性概述。

本执行摘要首先将心肺体外迴圈装置置于心臟外科手术的广泛领域中进行分析，指出装置的可靠性、生物相容性和手术效率直接影响临床结果。本文涵盖的装置包括用于心血管手术期间体外循环的装置和一次性用品，这些装置和用品与临床通讯协定、灌注师操作规范以及医疗机构的采购重点密切相关。随着医院和专科心臟中心的团队重新思考工作流程以优化治疗效果并控製成本，了解装置功能、使用者工程和病人安全之间的相互作用至关重要。

膜设计、泵浦机制、涂层和临床工作流程的进步如何全面重塑采购、临床实践和设备开发路径。

心肺体外迴圈装置领域正经历一场变革，其驱动力来自临床需求、技术创新以及对安全性和效率日益增长的期望。膜式氧合器材料的进步，包括中空纤维形状和板式设计的改进，在提升气体交换性能的同时，也减少了血液损伤。同时，泵浦技术也在不断发展，更耐用的离心机构和更精确的滚压帮浦控制，正在改变灌注师的工作流程和设备配置。

关税引发的供应链变化对零件采购、到货成本趋势、供应商多元化和采购弹性策略的连锁反应。

美国近期推出的政策措施为整个心肺体外迴圈设备供应链带来了新的挑战，影响成本结构、库存策略和采购决策。依赖跨境生产零件（例如用于氧合器膜的特殊聚合物、用于插管和泵壳的精密金属零件或药用级涂层）的製造商将受到关税的更大影响，关税可能导致进口成本增加。因此，许多供应商正在调整供应链结构，以在维持服务水准的同时维持利润率。

详细的細項分析揭示了产品系列、临床应用、最终用户环境和技术选择如何相互作用，从而塑造采购和部署模式。

基于细分市场的详细分析为产品开发、临床应用和销售策略提供了切实可行的见解。按产品类型划分，市场包括附件、插管、过滤器、氧合器和帮浦。附件包括储液器和导管，而插管则分为动脉插管和静脉插管，设计用于满足不同的解剖结构和流量需求。过滤器包括血液浓缩器和白血球去除过滤器，它们在体液管理和发炎调节中发挥不同的作用。氧合器则分为膜式和微孔式两种结构。在膜式氧合器中，板式和中空纤维式结构在表面积、预充能力和气体传输效率方面各有优劣。泵浦则分为离心式和滚压式两种技术，每种技术在溶血风险、维护特性以及与辅助监测系统的兼容性方面都存在差异。

美洲、欧洲、中东和非洲以及亚太地区的监管多样性、采购惯例和临床能力如何影响商业化和服务策略？

区域趋势对美洲、欧洲、中东和非洲以及亚太市场的临床实践、监管路径和商业策略都有显着影响。在美洲，大规模医院系统和学术医疗中心主导医疗采购，它们要求设备具备强有力的临床疗效证据、完善的服务网络，并能与电子健康记录和灌注监测平台无缝整合。该地区的支付模式和医院采购週期旨在确保设备的持久性能，并与供应商建立长期伙伴关係。

成熟製造商、专业创新者和以服务为导向的供应商之间的竞争行为和策略应对措施决定了市场领导地位和商业性差异化。

心肺体外迴圈设备领域的竞争动态呈现出多元化的特点，既有成熟的外科医疗设备製造商，也有专业的体外循环系统供应商，还有专注于利基创新技术的参与企业。成熟的製造商拥有涵盖一次性产品、大型设备和综合服务合约的广泛产品组合，导致转换成本高且产品生命週期较长。同时，中小企业和Start-Ups则透过新型薄膜材料、低预充氧器设计以及先进的泵浦控制演算法等创新技术脱颖而出，吸引专科医疗中心和研究型医院的目光。

为製造商和供应商提供可操作的策略重点，以优化其产品组合、保障供应链、产生临床证据、扩大服务范围并实现永续性目标。

产业领导企业可以采取一系列切实可行的优先事项，在应对营运限制的同时，巩固市场地位并支持临床疗效。首先，他们可以优先精简产品组合，使产品复杂性与核心终端使用者需求相匹配，减少缺乏临床证据区分的SKU，并将创新重点放在新生儿、儿童或成人细分市场需要独特解决方案的领域。其次，他们可以透过关键零件供应商多元化和协商合约保障措施来降低关税和物流波动风险，从而投资于供应链韧性。

为了检验营运洞察并为战略重点的製定提供信息，我们采用了一种严格的混合方法，结合了对临床医生的访谈、监管审查和技术文献。

本分析的研究基础是将对临床医生、灌注技师、采购经理和行业高管的定性访谈与监管文件、技术白皮书和同行评审的临床文献进行二次检验相结合。主要研究聚焦于代表性的医院、心臟中心和门诊手术中心，旨在了解医疗设备的实际表现、临床医师的偏好、服务期望和采购限制。访谈样本刻意纳入了同时服务成人和儿童患者的灌注技师，以全面了解医疗设备在所有临床领域的表现。

整合策略挑战，展示技术、供应链韧性和有针对性的商业性方法如何整合，以支援临床部署和营运稳定性。

总之，心肺体外迴圈设备市场正处于一个转折点，技术进步、政策压力和不断变化的临床需求相互交织，重塑采购和临床实践。氧合器设计、帮浦机制和表面涂层的进步带来了切实的临床效益，但其成功应用需要与服务基础设施、临床医生培训和筹资策略进行精心协调。关税导致的供应链调整凸显了采购多元化和提高零件来源透明度的必要性，而不同地区在法规和临床能力方面的差异则要求采取因地制宜的市场策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：心肺体外迴圈装置市场：依产品类型划分

  • 配件
    • 水库
    • 管子
  • 套管
    • 动脉
    • 静脉
  • 筛选
    • 血液浓缩器
    • 白血球过滤器
  • 氧合器
    • 电影
      • 平板型
      • 中空纤维
    • 微孔
  • 泵浦
    • 离心式
    • 滚筒

第九章：心肺体外迴圈装置市场：依技术划分

  • 涂层类型
    • 肝素涂层
    • 未涂层
  • 操作模式
    • 非脉衝型
    • 脉衝型

第十章：心肺体外迴圈装置市场：依应用领域划分

  • 成人版
  • 新生
  • 儿童

第十一章心肺体外迴圈装置市场：依最终用户划分

  • 门诊手术中心
  • 心臟外科中心
  • 医院

第十二章心肺体外迴圈装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章心肺体外迴圈装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章心肺体外迴圈装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国心肺体外迴圈机市场

第十六章：中国心肺体外迴圈机市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Beijing ZKSK Technology Co., Ltd.
  • Braile Biomedica
  • Brightwake Limited
  • Chalice Medical Ltd.
  • Fresenius Kabi
  • Getinge AB
  • Global Blood Resources, LLC
  • Johnson & Johnson Services, Inc.
  • LivaNova PLC
  • MAQUET Holding BV & Co. KG.
  • MC3 Cardiopulmonary
  • Medtronic Plc
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Owgels Group
  • Precision Medical, Inc.
  • ProCell Surgical Inc.
  • Senko Medical Instrument Manufacturing Co.,Ltd.
  • Sorin Group
  • Stryker Corporation
  • Technowood Corporation
  • Teleflex Incorporated
  • Terumo Group
  • Xenios AG
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-757B1C9CB0B8

The Cardiopulmonary Bypass Equipment Market was valued at USD 329.74 million in 2025 and is projected to grow to USD 342.63 million in 2026, with a CAGR of 4.74%, reaching USD 456.10 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 329.74 million
Estimated Year [2026] USD 342.63 million
Forecast Year [2032] USD 456.10 million
CAGR (%) 4.74%

A strategic overview placing cardiopulmonary bypass equipment within clinical practice, procurement priorities, technological progress and institutional decision frameworks

This executive summary opens by situating cardiopulmonary bypass equipment within the broader continuum of cardiac surgical care, where device reliability, biocompatibility, and procedural efficiency directly influence clinical outcomes. The equipment set covered spans devices and disposables that enable extracorporeal circulation during cardiac procedures, and it interacts closely with clinical protocols, perfusionist practice, and institutional procurement priorities. As teams across hospitals and specialized cardiac centers recalibrate workflows to optimize outcomes and contain costs, understanding the interplay among device functionality, user ergonomics, and patient safety has become essential.

Clinical adoption is shaped by both micro-level operational needs-such as ease of setup, priming volumes, and compatibility with monitoring systems-and macro-level forces including regulatory scrutiny and supply chain resilience. Technological advances in oxygenator membrane design and pump mechanics have reduced complication rates and simplified perioperative management, yet they have also introduced new decision criteria around training, disposables inventory, and vendor consolidation. Consequently, hospital administrators and perfusion leaders must synthesize clinical performance data with procurement considerations to select systems that align with institutional case mix and long-term capital plans.

The introduction concludes by framing the remainder of this summary as a practical synthesis: it highlights structural shifts, policy influences, segmentation nuances, regional dynamics, competitor behaviors, and targeted recommendations that together form a foundation for immediate strategic action by manufacturers, providers, and investors.

How advancements in membrane design, pump mechanics, coatings, and clinical workflows are collectively reshaping procurement, clinical practice, and device development pathways

The landscape for cardiopulmonary bypass equipment is undergoing transformative shifts driven by converging clinical priorities, engineering innovation, and heightened expectations for safety and efficiency. Advances in membrane oxygenator materials, including the refinement of hollow fiber geometries and flat plate designs, are delivering improved gas exchange characteristics while reducing blood trauma. At the same time, pump technologies have evolved with more durable centrifugal mechanics and more precise roller pump controls, altering perfusionist workflows and inventory configurations.

Beyond device evolution, systemic change is evident in the emphasis on coatings and surface treatments to mitigate thrombogenicity. Heparin-coated circuits and alternative biocompatible coatings are increasingly considered where anticoagulation management is complex, creating a differentiated value proposition between coated and non-coated systems. Mode of operation considerations-non-pulsatile versus pulsatile flow-are also influencing hospital purchasing decisions as clinicians weigh hemodynamic fidelity against device complexity and cost of disposables.

Operationally, there is a clear shift toward integrated circuit sets and single-use platforms that promise faster turnover and reduced contamination risk, but these benefits must be balanced against waste management and sustainability goals. In parallel, adoption patterns in neonatal and pediatric subsegments demand specialized cannulae and oxygenators sized for lower flow volumes and different priming strategies, prompting suppliers to refine product families to match patient demographics. Taken together, these shifts are driving a more nuanced procurement dialogue that places patient safety, clinician experience, and lifecycle total cost at the center of equipment selection.

The ripple effects of tariff-induced supply chain shifts on component sourcing, landed cost dynamics, supplier diversification, and procurement resilience strategies

Recent tariff developments originating from United States policy actions have introduced novel considerations across supply chains for cardiopulmonary bypass equipment, affecting cost structures, inventory strategies, and sourcing decisions. Manufacturers that rely on cross-border production of components such as specialized polymers for oxygenator membranes, precision metalwork for cannulae and pump housings, or pharmaceutical-grade coatings face increased exposure to duties that can alter landed costs. As a result, many suppliers are reassessing their supply chain architectures to preserve margin while maintaining service levels.

Procurement teams at hospitals and cardiac centers are responding by expanding supplier qualification frameworks and prioritizing dual-source strategies that reduce single-vendor risk. Where tariffs increase the relative cost of imported components, some original equipment manufacturers are accelerating localization efforts or renegotiating contracts to include tariff pass-through clauses. These measures underscore a shift from purely price-driven sourcing to a more resilient procurement posture that values lead-time assurance and component traceability.

Regulatory and contracting effects are also apparent: purchasing groups and health systems increasingly require transparency on the origin of components and warranty implications when manufacturing locations change. Clinicians and perfusion teams may face transition periods when product specifications shift due to component substitutions intended to mitigate tariff impacts. Therefore, institutional stakeholders should plan for validation cycles, training refreshers, and inventory buffers to avoid disruptions to surgical schedules while suppliers pursue longer-term realignment of manufacturing footprints.

Deep segmentation analysis revealing how product families, clinical applications, end-user environments, and technology choices interact to shape procurement and adoption patterns

Analyzing the market through detailed segmentation reveals actionable implications for product development, clinical adoption, and sales strategies. When viewed by product type, the landscape encompasses Accessories, Cannulae, Filters, Oxygenators, and Pumps; Accessories include Reservoirs and Tubing, and Cannulae comprise Arterial and Venous variants designed for distinct anatomical and flow requirements. Filters span Hemoconcentrators and Leukocyte Filters, which play differentiated roles in fluid management and inflammatory modulation, while Oxygenators are available in Membrane and Microporous constructs. Within membrane oxygenators, Flat Plate and Hollow Fiber architectures present tradeoffs in surface area, priming volume, and gas transfer efficiency. Pumps bifurcate into Centrifugal and Roller technologies, each with implications for hemolysis risk, maintenance profiles, and compatibility with ancillary monitoring systems.

Application segmentation differentiates adult, neonatal, and pediatric use cases, a distinction that materially affects device sizing, priming strategies, and circuit design. Neonatal and pediatric applications demand low-volume, high-precision solutions with specialized cannulae and oxygenator characteristics, whereas adult applications often emphasize durability and throughput. End user segmentation across Ambulatory Surgery Centers, Cardiac Surgery Centers, and Hospitals influences purchasing cycles and service expectations; ambulatory centers prioritize streamlined disposables and rapid turnover, cardiac surgery centers often demand high-performance customizable systems, and hospitals balance versatility with cost containment across broader case mixes.

Technology segmentation highlights coating type and mode of operation as pivotal decision variables. Coating options include Heparin Coated and Non Coated surfaces, with coated circuits offering a clinical rationale in patients at higher thrombotic risk or where lower systemic anticoagulation is desirable. Mode of operation divides into Non Pulsatile and Pulsatile systems, a choice that informs both physiological support characteristics and system complexity. Collectively, these segmentation lenses create a matrix that manufacturers and providers can use to align product portfolios with clinical needs, procurement constraints, and user preferences.

How regional regulatory diversity, procurement practices and clinical capacity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape commercialization and service strategies

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, institutional purchasing is characterized by large hospital systems and academic centers that demand robust evidence of clinical efficacy, strong service networks, and integration with electronic health records and perfusion monitoring platforms. Payment models and hospital procurement cycles in this region incentivize durable equipment performance and long-term vendor partnerships.

In Europe, Middle East & Africa, regulatory diversity and reimbursement variability require manufacturers to pursue harmonized clinical data that can support multiple approval pathways and value dossiers. Procurement in this region often emphasizes cost-effectiveness and lifecycle support across disparate healthcare delivery settings, from advanced cardiac centers to under-resourced facilities. The Asia-Pacific region is marked by rapid expansion of cardiac surgical capacity, investment in local manufacturing, and a growing emphasis on point-of-care optimization. Demand in Asia-Pacific is driven by both rising procedure volumes and evolving expectations for device affordability and local service capabilities.

Across regions, differences in clinical protocols, staff training paradigms, and waste management regulations create practical implications for device design and aftersales service. Manufacturers should calibrate market entry strategies to address regional reimbursement nuances, local clinical evidence generation, and the logistical requirements of providing responsive technical support. Strategic partnerships with regional distributors and investments in education for perfusion teams and surgical staff will be critical to unlock adoption across these heterogeneous markets.

Competitive behaviors and strategic responses among established manufacturers, focused innovators, and service-oriented providers that define market leadership and commercial differentiation

Competitive dynamics in the cardiopulmonary bypass equipment space are defined by a mix of established surgical device manufacturers, specialized perfusion system providers, and emerging technology entrants focused on niche innovations. Incumbent manufacturers leverage broad portfolios that span disposables, capital equipment, and integrated service contracts, creating high switching costs and extended product lifecycles. Meanwhile, smaller firms and start-ups push differentiation through novel membrane materials, low-priming-volume oxygenator designs, and advanced pump control algorithms that appeal to specialty centers and research hospitals.

Market participants are increasingly pursuing partnerships with clinical centers to co-develop next-generation systems, validate novel coatings, and run post-market surveillance studies that demonstrate real-world benefits. Supply chain collaborations, contract manufacturing models, and selective vertical integration are common strategic responses to procurement pressures and tariff exposure. Additionally, companies are investing in digital capabilities around device telemetry and predictive maintenance to enhance uptime and demonstrate value beyond the initial purchase.

For sales and commercial teams, the imperative is to articulate clinical value clearly to perfusionists, cardiac surgeons, and purchasing committees. This includes providing evidence of reduced complication rates, simplified workflows, and total cost of operation over relevant lifecycle horizons without relying solely on price as the differentiator. Firms that can combine robust clinical support, rapid technical service, and flexible contracting options will gain traction among hospital systems and specialized cardiac centers.

Practical strategic priorities for manufacturers and providers to optimize portfolios, secure supply chains, generate clinical evidence, expand service offerings, and address sustainability objectives

Industry leaders can pursue a set of actionable priorities to strengthen market positions and support clinical outcomes while addressing operational constraints. First, prioritize portfolio rationalization that aligns product complexity with core end-user needs, reducing SKUs where clinical evidence does not support differentiation and concentrating innovation where neonatal, pediatric, or adult subsegments demand unique solutions. Second, invest in supply chain resilience by diversifying suppliers of critical components and negotiating contractual protections that mitigate tariff and logistics volatility.

Third, deepen clinical partnerships that support evidence generation, including registries and collaborative studies that validate the benefits of membrane types, coatings, and pulsatile modality in relevant patient cohorts. Fourth, expand aftersales service models to include remote diagnostics, predictive maintenance, and training programs that reduce downtime and improve adoption confidence among perfusion staff. Fifth, tailor go-to-market approaches by region: emphasize regulatory alignment and value dossiers in Europe, performance and service in the Americas, and affordability plus local support in Asia-Pacific.

Finally, integrate sustainability and waste reduction into product and packaging design to meet institutional ESG goals and evolving procurement criteria. Executed together, these actions will help manufacturers and providers deliver measurable clinical benefits, strengthen commercial differentiation, and reduce operational risk in a shifting policy and supply chain environment.

A rigorous mixed-methods research approach combining clinician interviews, regulatory review, and technical literature to validate operational insights andinform strategic priorities

The research underlying this analysis synthesizes primary qualitative interviews with clinicians, perfusionists, procurement leaders, and industry executives alongside secondary validation from regulatory filings, technical white papers, and peer-reviewed clinical literature. Primary engagement focused on understanding real-world device performance, clinician preferences, service expectations, and procurement constraints across a representative set of hospitals, cardiac centers, and ambulatory surgical facilities. Interview sampling deliberately included perfusionists working with both adult and pediatric populations to capture device performance across the clinical spectrum.

Secondary sources provided technical context on membrane materials, pump mechanics, and coating science and were used to corroborate themes that emerged in interviews. The methodology applied a cross-sectional thematic analysis to identify recurring operational pain points, technology priorities, and procurement behaviors, and these themes were mapped against product segmentation and regional dynamics to derive actionable recommendations. To ensure accuracy and relevance, the analysis included iterative validation with subject matter experts and a review of recent regulatory communications that affect device design and labeling.

This combined approach produced a pragmatic synthesis designed to inform commercial strategy, clinical adoption pathways, and procurement decisions without relying on speculative market projections. The result is a robust evidence base that stakeholders can use to prioritize investments, modify go-to-market strategies, and align product roadmaps with clinical and operational realities.

Synthesis of strategic imperatives showing how technology, supply chain resilience and targeted commercial approaches converge to support clinical adoption and operational stability

In conclusion, the cardiopulmonary bypass equipment environment is at an inflection point where technology improvements, policy pressures, and evolving clinical expectations converge to reshape procurement and clinical practice. Advances in oxygenator design, pump mechanics, and surface coatings are delivering tangible clinical benefits, yet their successful adoption depends on careful alignment with service capabilities, clinician training, and procurement strategies. Tariff-induced supply chain adjustments have underscored the need for diversified sourcing and greater transparency around component provenance, while regional differences in regulation and clinical capacity call for tailored market approaches.

Manufacturers that emphasize resilient supply chains, focused product portfolios, robust clinical partnerships, and comprehensive aftersales support will be better positioned to meet the complex needs of hospitals, cardiac centers, and ambulatory facilities. Similarly, providers that integrate device selection with staff training, inventory management, and sustainability considerations will maximize clinical outcomes and operational efficiencies. The strategic actions outlined in this summary offer a roadmap for stakeholders seeking to balance innovation adoption with pragmatic operational risk management in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiopulmonary Bypass Equipment Market, by Product Type

  • 8.1. Accessories
    • 8.1.1. Reservoirs
    • 8.1.2. Tubing
  • 8.2. Cannulae
    • 8.2.1. Arterial
    • 8.2.2. Venous
  • 8.3. Filters
    • 8.3.1. Hemoconcentrators
    • 8.3.2. Leukocyte Filters
  • 8.4. Oxygenators
    • 8.4.1. Membrane
      • 8.4.1.1. Flat Plate
      • 8.4.1.2. Hollow Fiber
    • 8.4.2. Microporous
  • 8.5. Pumps
    • 8.5.1. Centrifugal
    • 8.5.2. Roller

9. Cardiopulmonary Bypass Equipment Market, by Technology

  • 9.1. Coating Type
    • 9.1.1. Heparin Coated
    • 9.1.2. Non Coated
  • 9.2. Mode Of Operation
    • 9.2.1. Non Pulsatile
    • 9.2.2. Pulsatile

10. Cardiopulmonary Bypass Equipment Market, by Application

  • 10.1. Adult
  • 10.2. Neonatal
  • 10.3. Pediatric

11. Cardiopulmonary Bypass Equipment Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Cardiac Surgery Centers
  • 11.3. Hospitals

12. Cardiopulmonary Bypass Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiopulmonary Bypass Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiopulmonary Bypass Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cardiopulmonary Bypass Equipment Market

16. China Cardiopulmonary Bypass Equipment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Beijing ZKSK Technology Co., Ltd.
  • 17.8. Braile Biomedica
  • 17.9. Brightwake Limited
  • 17.10. Chalice Medical Ltd.
  • 17.11. Fresenius Kabi
  • 17.12. Getinge AB
  • 17.13. Global Blood Resources, LLC
  • 17.14. Johnson & Johnson Services, Inc.
  • 17.15. LivaNova PLC
  • 17.16. MAQUET Holding B.V. & Co. KG.
  • 17.17. MC3 Cardiopulmonary
  • 17.18. Medtronic Plc
  • 17.19. MicroPort Scientific Corporation
  • 17.20. Nipro Corporation
  • 17.21. Owgels Group
  • 17.22. Precision Medical, Inc.
  • 17.23. ProCell Surgical Inc.
  • 17.24. Senko Medical Instrument Manufacturing Co.,Ltd.
  • 17.25. Sorin Group
  • 17.26. Stryker Corporation
  • 17.27. Technowood Corporation
  • 17.28. Teleflex Incorporated
  • 17.29. Terumo Group
  • 17.30. Xenios AG
  • 17.31. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 223. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 262. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 270. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 275. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 283. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA CARDIOPULMONARY